EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · MATERIAL CONTRACTS
MATERIAL CONTRACTS
The following are “material contracts” of the Company, as defined in National Instrument 51-102 -Continuous Disclosure Obligations, that are outstanding as of the date of this AIF:
| • | The Amended and Restated License Agreement between Auritec and Eupraxia USA dated October 9, 2018, as amended, and the Security Agreement between Auritec and Eupraxia USA dated March 31, 2020. |
| • | The warrant indenture between the Company and TSX Trust Company dated March 9, 2021. |
| • | The warrant indenture between the Company and TSX Trust Company dated April 20, 2022. |
Copies of the foregoing documents are available on SEDAR+ at www.sedarplus.ca.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.